Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Obese Progestin-insensitive Early-stage Endometrial Cancer Patients With Conservative Treatment
To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
• Have a confirmed initial pathological diagnosis based upon hysteroscopy: histologically prove well-differentiated EEC G1 without myometrial invasion
• BMI≥30kg/m2
• No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound
• Using progestin, any of the following therapy, as first-line treatment:
‣ Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not
⁃ Medroxyprogesterone acetate ≥ 250 mg qd using, combined with LNG-IUS inserted or not
⁃ LNG-IUS inserted
• Progestin-insensitive:
‣ remained with stable disease after 7 months of progestin use
⁃ did not achieve CR after 10 months of progestin use
• Have a desire for remaining reproductive function or uterus
• Good compliance with adjunctive treatment and follow-up